Frances P. Thorndike
Gründer bei BeHealth Solutions LLC
Profil
Frances P.
Thorndike is the founder of BeHealth Solutions LLC.
She previously worked as the Vice President-Medical Affairs at Pear Therapeutics, Inc. in 2023.
Aktive Positionen von Frances P. Thorndike
Unternehmen | Position | Beginn |
---|---|---|
BeHealth Solutions LLC
BeHealth Solutions LLC Packaged SoftwareTechnology Services BeHealth Solutions LLC develops and delivers digital health solutions to treat behavioral and mental health disorders, and eliminate unhealthy behaviors. It offers SHUTi, an interactive online program to improve the sleep of adults with insomnia; and BeWell+Sleep, an online behavioral sleep wellness program. The company was founded by Joseph L. Jennings III, Lee M. Ritterband and Frances P. Thorndike in 1998 and is headquartered in Charlottesville, VA. | Gründer | - |
Ehemalige bekannte Positionen von Frances P. Thorndike
Unternehmen | Position | Ende |
---|---|---|
PEAR THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2023 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
BeHealth Solutions LLC
BeHealth Solutions LLC Packaged SoftwareTechnology Services BeHealth Solutions LLC develops and delivers digital health solutions to treat behavioral and mental health disorders, and eliminate unhealthy behaviors. It offers SHUTi, an interactive online program to improve the sleep of adults with insomnia; and BeWell+Sleep, an online behavioral sleep wellness program. The company was founded by Joseph L. Jennings III, Lee M. Ritterband and Frances P. Thorndike in 1998 and is headquartered in Charlottesville, VA. | Technology Services |
Pear Therapeutics, Inc.
Pear Therapeutics, Inc. Medical SpecialtiesHealth Technology Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA. | Health Technology |